Mazdutide (IBI362/LY3305677) is a novel, once-weekly injectable drug that acts as a dual agonist for both GLP-1 and glucagon receptors, developed by Eli Lilly and Innovent Biologics, primarily for treating obesity/weight management and Type 2 Diabetes (T2D). It mimics natural hormones, leading to significant weight loss and improved blood sugar control, with strong results in clinical trials showing effectiveness in reducing BMI and HbA1c, and it’s already approved in China for these uses
. Common side effects are gastrointestinal (nausea, diarrhea, vomiting)
.
How it works
- Dual Action: It targets two key hormone receptors, GLP-1 (like semaglutide/tirzepatide) and glucagon receptors (like oxyntomodulin).
- Mechanism:Â This dual action helps reduce appetite, slow stomach emptying, and potentially increase energy expenditure, leading to weight loss.Â
Key benefits & results
- Significant Weight Loss:Â Clinical trials show substantial body weight reduction (up to over 20% in some studies) in overweight/obese adults.
- Improved Glycemic Control:Â Effectively lowers HbA1c and fasting glucose in T2D patients.
- Cardiometabolic Improvements:Â Also improves other risk factors like triglycerides, liver fat (MASH/NAFLD), and uric acid.
- Superiority to Others: Head-to-head studies show it can be more effective for weight loss and glycemic control than dulaglutide and potentially semaglutide.Â
Status & approvals
- Approved in China: Received approval in China (under the brand name Xinermei) in mid-2025 for weight management and T2D.
- Global Development:Â Undergoing extensive Phase 3 trials and development for broader use and other conditions like heart failure and sleep apnea.Â
Reviews
There are no reviews yet.